Availability and effectiveness of decision aids for supporting shared decision making in patients with advanced colorectal and lung cancer: Results from a systematic review. (8th May 2019)

• Record Type: Journal Article
• Authors: Spronk, Inge; Meijers, Maartje C.; Heins, Marianne J.; Francke, Anneke L.; Elwyn, Glyn; van Lindert, Anne; van Dulmen, Sandra; van Vliet, Liesbeth M.
• Is Part Of: European journal of cancer care. Volume 28:Number 3(2019)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2019-05-08
• Subjects: advanced colorectal cancer -- advanced lung cancer -- decision aid -- shared decision making; Cancer -- Nursing -- Periodicals; 616.994
• DOI: 10.1111/ecc.13079
• Languages: English
• ISSNs: 0961-5423

Abstract

Abstract: Introduction: Shared decision making is not always commonplace in advanced colorectal or lung cancer care. Decision aids (DAs) might be helpful. This review aimed (a) to provide an overview of DAs for patients with advanced colorectal or lung cancer and assess their availability; and (b) to assess their effectiveness if possible. Methods: A systematic literature search (PubMed/EMBASE/PsycINFO/CINAHL) and Internet and expert searches were carried out to identify relevant DAs. Data from the DAs included were extracted and the quality of studies, evidence (Grading of Recommendations Assessment, Development and Evaluation) and effectiveness (International Patient Decision Aid Standards) of DAs were determined. Results: Ten of the 12 DAs included (four colorectal cancer, four lung cancer and four generic) are still available. Most (9/12) were applicable throughout the disease pathway and usable for all decisions, or to the decision for supportive care with/without anti‐cancer therapy. Seven studies tested effectiveness. Effects on patient outcomes varied, but were generally weakly positive (e.g., DAs improved patient satisfaction) with low evidence. Study quality was fair to good. Conclusion: There is a lack of readily available DAs that have been demonstrated to be effective in advanced colorectal or lung cancer. Rigorous testing of the effects of currently available and future DAs, to improve patient outcomes, is urgently needed.